Literature DB >> 29030332

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Andrea Forschner1, Heike Niessner2, Yvonne Möller3, Peter Horak4, Martina Fröhlich5,6, Gregor Warsow7, Albrecht Stenzinger8,5, Stefan Fröhling4,5, Hanno Glimm4,5, Bernhard Klumpp9, Claus Garbe2, Tobias Sinnberg2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29030332     DOI： 10.1158/1078-0432.CCR-17-1480

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

Review 1.  The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.

Authors:  Erich Sabio; Timothy A Chan
Journal:  Genome Med       Date:  2019-07-24       Impact factor: 11.117

Review 2.  Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.

Authors:  Simone Camelliti; Valentino Le Noci; Francesca Bianchi; Claudia Moscheni; Francesca Arnaboldi; Nicoletta Gagliano; Andrea Balsari; Marina Chiara Garassino; Elda Tagliabue; Lucia Sfondrini; Michele Sommariva
Journal:  J Exp Clin Cancer Res       Date:  2020-11-09

Review 3.  Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.

Authors:  Peng Ding; Lu Wen; Fan Tong; Ruiguang Zhang; Yu Huang; Xiaorong Dong
Journal:  Cancer Drug Resist       Date:  2022-02-08

4.  Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Authors:  Tobias Sinnberg; Mitchell P Levesque; Jelena Krochmann; Phil F Cheng; Kristian Ikenberg; Francisco Meraz-Torres; Heike Niessner; Claus Garbe; Christian Busch
Journal:  Mol Cancer       Date:  2018-02-17       Impact factor: 27.401

5.  Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data.

Authors:  Jan Budczies; Nicole Pfarr; Eva Romanovsky; Volker Endris; Albrecht Stenzinger; Carsten Denkert
Journal:  BMC Bioinformatics       Date:  2018-04-24       Impact factor: 3.169

6.  Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.

Authors:  Ning Yang; Pin-Liang Zhang; Zeng-Jun Liu
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.